Brinton Pharma to launch anti-covid drug Molnupiravir
IMT News Desk
Each pack will have 40 capsules as the general recommended dosage is 800 mg twice/day for five daysBrinton Pharmaceutical will launch Molnupiravir with \the brand name ‘Molviton’ a promising drug for SARS-Cov-2 across the domestic market. Our brand Molviton would be available at all leading pharmacies and Covid treatment centres across the country by next week,” said Rahulkumar Darda, CMD, Brinton Pharmaceuticals.
Each pack will have 40 capsule as general recommended dosage is 800 mg twice/day for five days. Going forward the company is also working on 400 mg and 800 mg capsules. It will be available at all leading pharmacies and Covid treatment centres across the country.
"Along with the efficacy of the capsules, our goal also entailed ensuring affordability so that anyone needing it would be able to afford it. We are optimistic that the DCGI approval for rolling out this medicine would be a boon to many,” Rahulkumar Darda said. At a testing time when oral antivirals were the need of the hour to treat the coronavirus disease, Molunupiravir became the first such direct-acting medicine that proved to be highly effective in reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA with favourable safety and tolerability profile.Brinton, the Indian Pharmaceutical Multinational with a strong presence in the UK, US, Africa, France, Europe and the Middle East has interests in dermatology, paediatric, respiratory and family specialities. The company was in the news to ensure the availability of many covid-19 related drugs like Favipiravir (Faviton), Ivermectin(Scabover) and Doxycycline (Doxybond).
